Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia TORONTO, Jan. 23, 2020 /CNW/ - HLS Therapeutics...
Peak-year sales estimate increases to CAD$200-300 million, from CAD$150-250 million Commercial launch expected to take place in the mid-February 2020 timeframe Vascepa is the subject of numerous...
Health Canada approval follows priority review for Vascepa Vascepa becomes the first and only HC-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that the Endocrinologic and...
Revenue of $13.4 million, Adjusted EBITDA of $8.0 million and Cash from Operations of $6.8 million Paid a quarterly dividend of C$0.05 per outstanding common share Subsequent to quarter-end,...